Beryl Therapeutics
Longmont
About Beryl Therapeutics
Beryl Therapeutics goal is to open up a new frontier in bone health based on the revelation that lipids are crucial signaling molecules that play a role in bone mass regulation. Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density caused by disease or natural aging.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $250.0K
- Last round: Grant (May 2023)
- Website: beryltherapeutics.com
- Phone: (212) 681-8307
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/beryl-therapeutics-86840 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.